Healthcare
Live Price
Offline$14.75
-1.99% today
1Y Change
+1094.44%
Window
Jun 26, 2025 → Jun 24, 2026
Coverage: 249 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Erasca, Inc. (ERAS) is a Healthcare stock with a market cap of $3.10B and listed on NASDAQ. The stock last traded around $14.75 and up 1094.4% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +36.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +36.2%, free cash flow +27.6% with operating margin 0.0% and ROIC -37.8%. Stock Foundry combines ERAS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ERAS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ERAS Max Drawdown
-59.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ERAS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$122.8M
+49.4% YoY
Free Cash Flow
-$98.5M
+17.8% YoY
Revenue Growth
+0.0%
EPS Growth
+36.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -3M | 0 | -4M | -3M | -829K |
| Operating Income | -131M | -180M | -142M | -247M | -125M |
| EBITDA | -128M | -153M | -121M | -240M | -122M |
| Net Income | -125M | -162M | -125M | -243M | -123M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74M | 68M | 93M | 284M | 360M |
| Total Assets | 396M | 503M | 395M | 515M | 501M |
| Total Liabilities | 71M | 79M | 79M | 103M | 45M |
| Shareholder Equity | 325M | 423M | 317M | 412M | 457M |
| Total Debt | 47M | 52M | 56M | 55M | 19M |
| Net Debt | -27M | -16M | -37M | -229M | -342M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
80M
+22.9% YoY
Capital Expenditures
19M
-14.1% YoY
Free Cash Flow
98M
+17.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-34.5%
Debt / Equity
0.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.